In vivo tumor inhibitory effects of nutritional rice bran supplement MGN-3/biobran on ehrlich carcinoma-bearing mice

Nutrition and Cancer

Volumn 60, Issue 2, 2008, Pages 235-244

  El Din, Nariman K Badr ^a   Noaman, Eman ^b   Ghoneum, Mamdooh ^c  

^a Mansoura University   (Egypt)

^b NATIONAL CENTER FOR RADIATION RESEARCH AND TECHNOLOGY   (Egypt)

^c CHARLES R DREW UNIVERSITY OF MEDICINE AND SCIENCE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARABINOXYLAN; BIOBRAN; CYTOKINE; GAMMA INTERFERON; INTERLEUKIN 10; MGN 3; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER INHIBITION; CELL ACTIVITY; CELL COUNT; CONTROLLED STUDY; CYTOKINE PRODUCTION; DOWN REGULATION; DRINKING BEHAVIOR; DRUG EFFECT; DRUG MECHANISM; EHRLICH ASCITES TUMOR; FEEDING BEHAVIOR; FEMALE; FLOW CYTOMETRY; HISTOPATHOLOGY; IMMUNOMODULATION; IN VIVO STUDY; INOCULATION; MOUSE; NATURAL KILLER CELL; NONHUMAN; NUTRITION; PROTEIN BLOOD LEVEL; RICE BRAN; SINGLE DRUG DOSE; SOLID TUMOR; THIGH; TUMOR GROWTH; TUMOR VOLUME;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CARCINOMA, EHRLICH TUMOR; CYTOKINES; FEMALE; FLOW CYTOMETRY; INJECTIONS, INTRAPERITONEAL; INTERFERON TYPE II; KILLER CELLS, NATURAL; MICE; ORYZA SATIVA; RANDOM ALLOCATION; TUMOR NECROSIS FACTOR-ALPHA; XYLANS;

ANIMALIA; MUS;

EID: 41349086441     PISSN: 01635581     EISSN: None     Source Type: Journal    
DOI: 10.1080/01635580701627285     Document Type: Article

References (63)

1. Abdullaev FI, Rivera-Luna R, Roitenburd-Belacortu V, and Espinosa-Aguirre J: Pattern of childhood cancer mortality in Mexico. Arch Med Res 31, 526-531, 2000.
2. Marty M, Mignot L, Gisselbrecht G, Morvan F, Gorins A, et al.: Teratogenic and mutagenic risks of radiotherapy: when and how to prescribe contraception. Contracept Fertil Sex (Paris) 13(1Suppl), 181-186, 1985.
3. Mills KH, Greally JF, Temperley IJ, and Mullins GM: Haematological and immune suppressive effects of total body irradiation in the rat. Ir J Med Sci 149, 201-208, 1980.
4. Sanderson BJ, Ferguson LR, and Denny WA: Mutagenic and carcinogenic properties of platinum-based anticancer drugs. Mutat Res 355, 59-70, 1996.
5. Santin AD, Hermonat PL, Ravaggi A, Bellone S, Roman J, et al.: Effects of concurrent cisplatinum administration during radiotherapy vs. radiotherapy alone on the immune function of patients with cancer of the uterine cervix. Int J Radiat Oncol Biol Phys 48, 997-1006, 2000.
6. Lee E and Surh YJ: Induction of apoptosis in HL-60 cells by pungent vanilloids, [6]-gingerol and [6]-paradol. Cancer Lett 134, 163-168, 1998.
7. Lamm DL and Riggs DR: The potential application of Allium sativum (garlic) for the treatment of bladder cancer. Urol Clin North Am 27, 157-162, xi, 2000.
8. Fleischauer AT, Poole C, and Arab L: Garlic consumption and cancer prevention: meta-analyses of colorectal and stomach cancers. Am J Clin Nutr 72, 1047-1052, 2000.
9. Sigounas G, Anagnostou A, and Steiner M: dl-alpha-tocopherol induces apoptosis in erythroleukemia, prostate, and breast cancer cells. Nutr Cancer 28, 30-35, 1997.
10. Halicka D, Ardelt B, Juan G, Mittelman A, and Chen S: Apoptosis and cell cycle effects induced by extracts of the Chinese herbal preparation PC SPES. Int J Oncol 11, 437-448, 1997.
11. Hattori TS, Komatsu N, Shichijo S, and Itoh K: Protein-bound polysaccharide K induced apoptosis of the human Burkitt lymphoma cell line, Namalwa. Biomed Pharmacother 58, 226-230, 2004.
12. Ghoneum M and Gollapudi S: Induction of apoptosis in breast cancer cells by Saccharomyces cerevisiae, the baker's yeast, in vitro. Anticancer Res 24, 1455-1463, 2004.
13. Ghoneum M, Hamilton J, Brown J, and Gollapudi S: Human squamous cell carcinoma of the tongue and colon undergoes apoptosis upon phagocytosis of Saccharomyces cerevisiae, the baker's yeast, in vitro. Anticancer Res 25, 981-989, 2005.
14. Ghoneum M and Gollapudi S: Modified arabinoxylan rice bran (MGN-3/Biobran) enhances yeast-induced apoptosis in human breast cancer cells in vitro. Anticancer Res 25, 859-870, 2005.
15. Ghoneum M: Anti-HIV activity in vitro of MGN-3, an activated arabinoxylane from rice bran. Biochem Biophys Res Commun 243, 25-29, 1998.
16. Ghoneum M and Abedi S: Enhancement of natural killer cell activity of aged mice by modified arabinoxylan rice bran (MGN-3/Biobran). J Pharm Pharmacol 56, 1581-1588, 2004.
17. Ghoneum, M: Enhancement of human natural killer cell activity by modified arabinoxylane from rice bran (MGN-3). Int J Immunother 14, 89-99, 1998.
18. Ghoneum M and Brown J: NK immunorestoration of cancer patients by MGN-3, a modified arabinoxylan rice bran (study of 32 patients followed for up to 4 years). In Anti-aging Medical Therapeutics, Volume III, Klatz R, Goldman R (eds). Marina del Rey, CA: Health Quest Publications, 1999, pp. 217-226.
19. Ghoneum M and Jewett A: Production of tumor necrosis factor-alpha and interferon-gamma from human peripheral blood lymphocytes by MGN-3, a modified arabinoxylan from rice bran, and its synergy with interleukin-2 in vitro. Cancer Detect Prev 24, 314-324, 2000.
20. Ghoneum M and Matsuura M: Augmentation of macrophage phagocytosis by modified arabinoxylan rice bran (MGN-3/biobran). Int J Immunopathol Pharmacol 17, 283-292, 2004.
21. Ghoneum M and Gollapudi S: Modified arabinoxylan rice bran (MGN-3/Biobran) sensitizes human T cell leukemia cells to death receptor (CD95)-induced apoptosis. Cancer Lett 201, 41-49, 2003.
22. Quanhong L, Caili F, Yukui R, Guanghui H, and Tongyi C: Effects of protein-bound polysaccharide isolated from pumpkin on insulin in diabetic rats. Plant Foods Hum Nutr 60, 13-16, 2005.
23. Tribukait B, Moberger G, and Zetterberg A: Methodological aspects of rapid flow cytofluorometry for DNA analysis of human urinary bladder cells. In Pulse-Cytophotometry, Part I. Ghent, Belgium: European press, Medicon, 1975, pp. 50-60.
24. Itoh K, Suzuki R, Umezu Y, Hanaumi K, and Kumagai K: Studies of murine large granular lymphocytes: II. tissue, strain, and age distributions of LGL and LAL. J Immunol 129, 395-405, 1982.
25. Segura JA, Barbero LG, and Marquez J: Ehrlich ascites tumour unbalances splenic cell populations and reduces responsiveness of T cells to Staphylococcus aureus enterotoxin B stimulation. Immunol Lett 74, 111-115, 2000.
26. Piemonti L, Zerbi A, and Di Carlo V: Strategies for tumor immune escape. Drugs Today (Barc) 39, 701-724, 2003.
27. Queiroz ML, Valadares MC, Bincoletto C, and Dieamant GC: Ehrlich ascites tumor as a tool in the development of compounds with immunomodulatory properties. Immunopharmacol Immunotoxicol 26, 511-525, 2004.
28. Herberman RB: Natural killer (NK) cells and their possible roles in resistance against disease. Clin Immunol Rev 1, 1-65, 1981.
29. Roder JC and Pross HF: The biology of the human natural killer cell. J Clin Immunol 2, 249-263, 1982.
30. Contasta I, Berghella AM, Pellegrini P, and Adorno D: Passage from normal mucosa to adenoma and colon cancer: alteration of normal sCD30 mechanisms regulating TH1/TH2 cell functions. Cancer Biother Radiopharm 18, 549-557, 2003.
31. Baron S, Tyring SK, Fleischmann WR Jr, Coppenhaver DH, Niesel DW, et al.: The interferons. Mechanisms of action and clinical applications. JAMA 266, 1375-1383, 1991.
32. Cha SS, Kim MS, Choi YH, Sung BJ, Shin NK, et al.: 2.8 A resolution crystal structure of human TRAIL, a cytokine with selective antitumor activity. Immunity 11, 253-261, 1999.
33. Borish LC and Steinke JW: 2. Cytokines and chemokines. J Allergy Clin Immunol 111(2 Suppl), S460-S475, 2003.
34. Nishiguchi S, Kuroki T, Nakatani S, Morimoto H, Takeda T, et al.: Randomised trial of effects of interferon-alpha on incidence of hepatocellular carcinoma in chronic active hepatitis C with cirrhosis. Lancet 346, 1051-1055, 1995.
35. Yoshida H, Shiratori Y, Moriyama M, Arakawa Y, Ide T, et al.: Interferon therapy reduces the risk for hepatocellular carcinoma: national surveillance program of cirrhotic and noncirrhotic patients with chronic hepatitis C in Japan. IHIT Study Group. Inhibition of hepatocarcinogenesis by interferon therapy. Ann Intern Med 131, 174-181, 1999.
36. Kashiwagi K, Furusyo N, Kubo N, Nakashima H, Nomura H, et al.: A prospective comparison of the effect of interferon-alpha and interferon-beta treatment in patients with chronic hepatitis C on the incidence of hepatocellular carcinoma development. J Infect Chemother 9, 333-340, 2003.
37. Biron CA, Nguyen KB, Pien GC, Cousens LP, and Salazar-Mather TP: Natural killer cells in antiviral defense: function and regulation by innate cytokines. Annu Rev Immunol 17, 189-220, 1999.
38. von Hoegen P: Synergistic role of type I interferons in the induction of protective cytotoxic T lymphocytes. Immunol Lett 47, 157-162, 1995.
39. Hiroishi K, Tuting T, and Lotze MT: IFN-alpha-expressing tumor cells enhance generation and promote survival of tumor-specific CTLs. J Immunol 164, 567-572, 2000.
40. Ohzato H, Monden M, Yoshizaki K, Ogata A, Nishimoto N, et al.: Systemic production of interleukin-6 following acute inflammation. Biochem Biophys Res Commun 197, 1556-1562, 1993.
41. Kawakami Y, Hayashi J, Ueno K, Ohmiya M, Kishihara Y, et al.: Elevation of serum soluble interleukin-2 receptor levels in patients with hepatitis C virus infection. Fukuoka Igaku Zasshi 88, 274-282, 1997.
42. Furusyo N, Hayashi J, Ohmiya M, Sawayama Y, Kawakami Y, et al.: Differences between interferon-alpha and -beta treatment for patients with chronic hepatitis C virus infection. Dig Dis Sci 44, 608-617, 1999.
43. Fiorentino DF, Zlotnik A, Vieira P, Mosmann TR, Howard M, et al.: IL-10 acts on the antigen-presenting cell to inhibit cytokine production by Th1 cells. J Immunol 146, 3444-3451, 1991.
44. Fiorentino DF, Bond MW, and Mosmann TR: Two types of mouse T helper cell: IV. th2 clones secrete a factor that inhibits cytokine production by Th1 clones. J Exp Med 170, 2081-2095, 1989.
45. Hsu DH, de Waal Malefyt R, Fiorentino DF, Dang MN, Vieira P, et al.: Expression of interleukin-10 activity by Epstein-Barr virus protein BCRF1. Science 250, 830-832, 1990.
46. Hsu DH, Moore KW, and Spits H: Differential effects of IL-4 and IL-10 on IL-2-induced IFN-gamma synthesis and lymphokine-activated killer activity. Int Immunol 4, 563-569, 1992.
47. Whiteside TL and Herberman RB: The role of natural killer cells in immune surveillance of cancer. Curr Opin Immunol 7, 704-710, 1995.
48. Herberman RB: Cancer immunotherapy with natural killer cells. Semin Oncol 29(7Suppl), 27-30, 2002.
49. Wu J and Lanier LL. Natural killer cells and cancer. Adv Cancer Res 90, 27-56, 2003.
50. Arase H, Arase N, and Saito T: Fas-mediated cytotoxicity by freshly isolated natural killer cells. J Exp Med 181, 1235-1238, 1995.
51. Velthuis JH, Gavric Z, de Bont HJ, and Nagelkerke JF: Impaired activation of caspases and prevention of mitochondrial dysfunction in the metastatic colon carcinoma CC531s-m2 cell line. Biochem Pharmacol 69, 463-471, 2005.
52. Walczak H and Krammer PH: The CD95 (APO-1/Fas) and the TRAIL (APO-2L) apoptosis systems. Exp Cell Res 256, 58-66, 2000.
53. Takahara K and Sano K: The life prolongation and QOL improvement effect of rice bran arabinoxylan derivative (MGN-3,BioBran) for progressive cancer. Clin Pharmcol Ther 14, 267-271, 2004.
54. Meurs EF, Galabru J, Barber GN, Katze MG, and Hovanessian AG: Tumor suppressor function of the interferon-induced double-stranded RNA-activated protein kinase. Proc Natl Acad Sci USA 90, 232-236, 1993.
55. Yano H, Iemura A, Haramaki M, Ogasawara S, Takayama A, et al.: Interferon alfa receptor expression and growth inhibition by interferon alfa in human liver cancer cell lines. Hepatology 29, 1708-1717, 1999.
56. Murphy D, Detjen KM, Welzel M, Wiedenmann B, and Rosewicz S: Interferon-alpha delays S-phase progression in human hepatocellular carcinoma cells via inhibition of specific cyclin-dependent kinases. Hepatology 33, 346-356, 2001.
57. Suk K, Kim YH, Chang I, Kim JY, Choi YH, et al.: IFNalpha sensitizes ME-180 human cervical cancer cells to TNFalpha-induced apoptosis by inhibiting cytoprotective NF-kappaB activation. FEBS Lett 495, 66-70, 2001.
58. Sasagawa T, Hlaing M, and Akaike T: Synergistic induction of apoptosis in murine hepatoma Hepa1-6 cells by IFN-gamma and TNF-alpha. Biochem Biophys Res Commun 272, 674-680, 2000.
59. Konjevic G, Jovic V, Jurisic V, Radulovic S, Jelic S, et al.: IL-2-mediated augmentation of NK-cell activity and activation antigen expression on NK- and T-cell subsets in patients with metastatic melanoma treated with interferon-alpha and DTIC. Clin Exp Metastasis 20, 647-655, 2003.
60. Smyth MJ, Taniguchi M, and Street SE: The anti-tumor activity of IL-12: mechanisms of innate immunity that are model and dose dependent. J Immunol 165, 2665-2670, 2000.
61. Carson WE, Fehniger TA, Haldar S, Eckhert K, Lindemann MJ, et al.: A potential role for interleukin-15 in the regulation of human natural killer cell survival. J Clin Invest 99, 937-943, 1997.
62. Allavena P, Giardina G, Sen S, Colella G, Broggini M, et al.: IFN-beta partially counteracts inhibition of natural killer activity induced by some antitumor agents. J Interferon Cytokine Res 18, 87-93, 1998.
63. Appasamy R, Bryant J, Hassanein T, Van Thiel DH, and Whiteside TL: Effects of therapy with interferon-alpha on peripheral blood lymphocyte subsets and NK activity in patients with chronic hepatitis C. Clin Immunol Immunopathol 73, 350-357, 1994.